<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439215</url>
  </required_header>
  <id_info>
    <org_study_id>FoRT 01/2016</org_study_id>
    <nct_id>NCT03439215</nct_id>
  </id_info>
  <brief_title>PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer</brief_title>
  <acronym>PFROST</acronym>
  <official_title>PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer: a Phase II Trial (PFROST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Ricerca Traslazionale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical research technology Srl</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Ricerca Traslazionale</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study assessing response rate to PF-06463922 in patients with ROS1&#xD;
      translocation resistant to previous crizotinib therapy. Eligible patients will be treated&#xD;
      with the study drug until disease progression, unacceptable toxicity or patient refusal.&#xD;
      Disease assessment will be performed every 8 weeks according to RECIST criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PF-06463922 is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain&#xD;
      penetration. The results showed that PF-06463922 is most potent against ROS1 and ALK, with&#xD;
      selectivity ratios &gt;100-fold for ROS1 over the 204 kinases tested. A recent study has&#xD;
      investigated the activity of PF-06463922 against the crizotinib-resistant ROS1G2032R mutation&#xD;
      in both recombinant enzyme and cell-based assays. PF-06463922 effectively inhibited the&#xD;
      catalytic activity of recombinant ROS1G2032R and the CD74-ROS1G2032R fusion kinase in BaF3&#xD;
      cells. This effect translated directly into an antiproliferative response. These results,&#xD;
      together with its exquisite ROS1 potency and ability to suppress the resistant ROS1&#xD;
      mutations, supports the clinical evaluation of PF-06463922 in ROS1-positive NSCLC, including&#xD;
      patients who have developed resistance to crizotinib because of the acquired G2032R mutation&#xD;
      and/or brain metastases.&#xD;
&#xD;
      This is a phase II study assessing response rate to PF-06463922 in patients with ROS1&#xD;
      translocation resistant to previous crizotinib therapy. Eligible patients will be treated&#xD;
      with the study drug until disease progression, unacceptable toxicity or patient refusal.&#xD;
      Disease assessment will be performed every 8 weeks according to RECIST criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 13, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate to PF-06463922 in patients with ROS1 translocation resistant to crizotinib</measure>
    <time_frame>From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months</time_frame>
    <description>Response rate to PF-06463922 in patients with ROS1 translocation resistant to crizotinib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS), The length of time during and after the treatment of a disease,that a patient lives with the disease but it doesn't get worse.</measure>
    <time_frame>From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months</time_frame>
    <description>Progression-free survival (PFS) will be calculated from the time between the baseline/start of treatment visit to the time of first occurrence of progressive disease (PD) or death from any cause. Patients who have neither progressed nor died at time of analysis will be censored at the date of last tumor assessment where non progression was documented (i.e. CR, PR or SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS): Time from the start of treatment until death from any cause</measure>
    <time_frame>From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months</time_frame>
    <description>Overall survival (OS) will be calculated from the time between the baseline/start of treatment visit to the date of death, irrespective of the cause of death. Patients still alive at the time of analysis will be censored at the date they were last known to be alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months</time_frame>
    <description>Patients will be closely monitored for signs and symptoms of potential adverse events, and will undergo frequent laboratory tests to assess lipids, pancreas, liver, kidney, and haematological function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with additional tumor biomarkers in tumor tissue or blood</measure>
    <time_frame>From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months</time_frame>
    <description>Correlation with additional tumor biomarkers in tumor tissue or blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Lorlatinb Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will be treated with Lorlatinib at the dose of 100 mg QD p.o.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorlatinib</intervention_name>
    <description>Lorlatinib is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration.</description>
    <arm_group_label>Lorlatinb Arm</arm_group_label>
    <other_name>Lorlatinb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent;&#xD;
&#xD;
          2. Male or female patient ages ≥ 18 years;&#xD;
&#xD;
          3. Histologically/cytologically confirmed diagnosis of NSCLC with evidence of ROS1&#xD;
             rearrangement;&#xD;
&#xD;
          4. Possibility to perform a new tumor biopsy or tumor tissue collected at the time or&#xD;
             after crizotinib failure;&#xD;
&#xD;
          5. Patient pretreated with crizotinib with evidence of disease progression during&#xD;
             crizotinib therapy;&#xD;
&#xD;
          6. At least one radiological measurable disease according to RECIST criteria;&#xD;
&#xD;
          7. At least 1 previous standard chemotherapy regimen;&#xD;
&#xD;
          8. Performance status 0-2 (ECOG);&#xD;
&#xD;
          9. Patient compliance to trial procedures&#xD;
&#xD;
         10. Adequate bone marrow function (ANC ≥ 1.5x109/L, platelets ≥ 100x109/L, haemoglobin &gt; 9&#xD;
             g/dl);&#xD;
&#xD;
         11. Adequate liver function (bilirubin &lt; grade 2, transaminases no more than 3xULN/&lt;5xULN&#xD;
             in present of liver metastases);&#xD;
&#xD;
         12. Normal level of alkaline phosphatase and creatinine;&#xD;
&#xD;
         13. If female: childbearing potential either terminated by surgery, radiation, or&#xD;
             menopause, or attenuated by use of approved contraceptive method [intrauterine&#xD;
             contraceptive device (IUD), birth control pills, or barrier device] during and for&#xD;
             ninety (90) days after end of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. No ROS1 rearrangement 2. No previous therapy with crizotinib; 3. No evidence of&#xD;
        crizotinib failure; 4. No post-crizotinib tumor tissue available; 5. Absence of any&#xD;
        measurable lesions; 6. No previous chemotherapy; 7. Concomitant radiotherapy or&#xD;
        chemotherapy; 8. Symptomatic brain metastases; 9. Diagnosis of any other malignancy during&#xD;
        the last 5 years, except for in situ carcinoma of cervix uteri and squamous cell carcinoma&#xD;
        of the skin; 10. Predisposing factors for acute pancreatitis (e.g., uncontrolled&#xD;
        hyperglycaemia, current gallstone disease, alcoholism); 11. History of extensive&#xD;
        disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or&#xD;
        interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis,&#xD;
        interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary&#xD;
        fibrosis (but not history of prior radiation pneumonitis); 12. Pregnancy or lactating&#xD;
        female; 13. Other serious illness or medical condition potentially interfering with the&#xD;
        study.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)- Oncologia Medica</name>
      <address>
        <city>Meldola</city>
        <state>Forlì- Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacro Cuore- Don Calabria Hospital- U.O.C. Oncologia Medica</name>
      <address>
        <city>Negrar</city>
        <state>Verona</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Toscano Tumori Ospedale San Donato- U.O.C. di Oncologia Medica Dipartimento di Oncologia USL-8</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale &quot;S.G. Moscati&quot;</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS A.O.U. San Martino- IST- Istituto Nazionale per la Ricerca sul Cancro- U.O.S. Tumori Polmonari</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia - Divisione di Oncologia Toracica</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico di Modena- Oncologia Ematologia e Malattie Apparato Respiratorio</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IRCCS- UOS Oncologia Toracica UOC. Oncologia Medica 2</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena- U.O. Oncologia medica</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Parma- Struttura Complessa di Oncologia Medica</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Perugia- S.C. Oncologia Medica</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Ravenna- Oncologia Medica</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot; Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST della Valle Olona - Ospedale di Saronno</name>
      <address>
        <city>Saronno</city>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. San Luigi Gonzaga</name>
      <address>
        <city>Torino</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ULSS 9 TREVISO-UOC Oncologia Medica</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico 'G.B.Rossi' Borgo Roma - A.O.U. Integrata (Giampaolo Tortora)- Oncologia Medica</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.cr-technology.com/fort/?studio_clinico=pfrost</url>
    <description>PFROST trial</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ROS1 positive</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

